Compumedics Ltd (ASX:CMP) CFO David Lawson tells Proactive revenues grew 12% to a record $42.4 million for FY23, compared to $37.8 million in FY22. He adds that substantial investment in commercialisation activities associated with the Somfit and MEG step-out growth opportunities continued in the period. Looking ahead the company anticipates revenues for FY24 will be more than $44 million and EBITDA is expected to be more than $5 million, with the growth driven primarily from its new SaaS product offering.
Compumedics clocks up record revenue in FY23
